2023 China Medtech Industry Outlook

Published on February 27, 2023

Building on ongoing in-depth discussions with leaders in the medtech industry, our 2023 China Medtech Outlook is now out, with key themes highlighted in the article below.  

Policy drivers: The positives and negatives

In September 2022, China unveiled a subsidized loan scheme amounting to 200 billion yuan (RMB) for hospitals to build up their hardware. This bodes well for medtech companies, especially in diagnosis, imaging, pathology, ICU, rehab, and clinical research. In fact, many medtech companies have reacted quickly to the new policy and launched various products and services to fully capitalize on it.

Meanwhile, volume-based procurement (VoBP), import substitution, and payment reform remain recurring themes that will continue to shape the industry going forward.

  • Results from the third round of national VoBP for spine orthopedics were released in September 2022 and show three noteworthy trends:
Continue reading on website
Other news

How to prepare your P&MA function for the future – current challenges and best-practice solutions

February 27, 2023
Is your P&MA function future ready? The increasing complexity of products, intensified competition, evolution of payers’ needs, and stricter healthcare systems are some of the factors that have increased the need to check in on your P&MA function!As we have followed this multifaceted evolution over the last few years, pricing and market access (P&MA) has shifted from a technical function to a stra

Frontiers of CGT in China

February 27, 2023
China is at the forefront of global cell and gene therapy (CGT) developmentAccording to Nature research in 2021, China accounts for over 50 percent of cell therapy trials worldwide. Today, there are around 400 ongoing CAR-T trials in China across a broad range of targets and diverse indications, from hematology/oncology to solid tumors.Among the frontrunners, Fosun Kite’s Yescarta and JW Therapeut